In this episode of SciBud, we delve into the latest breakthroughs in gastric cancer research, emphasizing a groundbreaking study that uncovers the role of specific proteins in treatment resistance. Host Rowan guides us through the intricacies of the NFATC2, SERPINE1, JAK3, and STAT3 signaling pathways and how they contribute to tumor aggressiveness and immune evasion, crucial factors for patients undergoing anti-PD-1 immunotherapy. With about a million new gastric cancer diagnoses each year, understanding these mechanisms is vital for improving patient outcomes. The study reveals that heightened levels of SERPINE1 not only correlate with worse prognoses but also establish a positive feedback loop that enhances tumor growth and shields it from immune responses. Most intriguingly, silencing SERPINE1 has the potential to increase the effectiveness of immunotherapy, paving the way for promising new treatment strategies. Join us as we break down these compelling findings and their implications for the future of gastric cancer therapy! Link to episode page with article citation: www.scibud.media/podcast/season/2025/episode/32
Fler avsnitt av SciBud: Emerging Discoveries from Bioimaging
Visa alla avsnitt av SciBud: Emerging Discoveries from BioimagingSciBud: Emerging Discoveries from Bioimaging med Galo Garcia finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
